Psoriatic Arthritis

The Psoriatic Arthritis pipeline: 48 tracked drugs, 38 approved for this indication.

38 approved / phase 46 Phase 32 Phase 22 Phase 1

Compare the share prices of listed companies in Psoriatic Arthritis →

Total attributable cost

$20.3B

$22,272/patient

Drug spend

$12.9B

$14,174/patient

How this is calculated ↗

All severities · US

The Psoriatic Arthritis pipeline

Key trial results for every approved and late-stage drug: Psoriatic Arthritis results by drug.

← all assets